Literature DB >> 12774288

Enantiomeric separation by HPLC of 1,4-dihydropyridines with vancomycin as chiral selector.

Gianpiero Boatto1, Maria Nieddu, Maria Virginia Faedda, Paolo de Caprariis.   

Abstract

The macrocyclic antibiotics represent a relatively new class of chiral selectors in CE, HPLC, and TLC. We have examined the use of the macrocyclic antibiotic vancomycin as a chiral selector in HPLC for the separation of 1,4-dihydropyridines (DHPs) calcium antagonists (CAs). Chromatographic data of six 1,4-dihydropyridine calcium channel blockers obtained on the vancomycin chiral stationary phase (Chirobiotic V) were compared with those obtained on an alpha(1)-acid glycoprotein (AGP) HPLC stationary phase. Optimization of pH and organic modifier was carried out in order to modulate the retention properties of each system. All chiral neutral DHPs were resolved on the AGP column, whereas on Chirobiotic V only basic DHPs showed a split peak. The analytical chromatographic procedure on Chirobiotic V proved suitable for semipreparative separation, since the separation factor on the analytical column was high enough to obtain pure enantiomers with high yields. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12774288     DOI: 10.1002/chir.10238

Source DB:  PubMed          Journal:  Chirality        ISSN: 0899-0042            Impact factor:   2.437


  2 in total

1.  Principal component analysis of HPLC retention data and molecular modeling structural parameters of cardiovascular system drugs in view of their pharmacological activity.

Authors:  Jolanta Stasiak; Marcin Koba; Leszek Bober; Tomasz Baczek
Journal:  Int J Mol Sci       Date:  2010-07-09       Impact factor: 5.923

2.  Quantitative determination of lercanidipine enantiomers in commercial formulations by capillary electrophoresis.

Authors:  Luciana Pereira Lourenço; Fernando Armani Aguiar; Anderson Rodrigo Moraes de Oliveira; Cristiane Masetto de Gaitani
Journal:  J Anal Methods Chem       Date:  2015-03-02       Impact factor: 2.193

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.